MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Poseida Therapeutics Inc. (NASDAQ PSTX)*
Organization & Developments: Poseida
Parents
Poseida Therapeutics Inc. (NASDAQ PSTX)*
Children
2017: High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells.
2020: Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
2020: Qiagen joins with T-cell biotech TScan to develop immune system test for COVID-19
2021: Poseida: Early Stage CAR-T And Gene Therapy Developer
2022: Poseida Therapeutics: Early Stage CAR-T Developer Seeing Big Pharma Interest_ seekingalpha.com
2023: Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful_ seekingalpha.com
2023: Poseida Therapeutics: Why I Am Still Holding On To The Stock Into 2024 (Rating Downgrade)
2024: Poseida Therapeutics Partners With Astellas: Worth Watching For Now
2024: Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
2024: Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Jumps
*Key People: Poseida
Finance & Acquisitions: Poseida